The Company is one of the largest Russian pharmaceutical industry investors. The cumulative volume of investments in projects to be completed by 2024 is over 23 bln rubles.
Pharmasyntez-Nord, Saint Petersburg
2021: Facility for research and production of biological drugs for the treatment of cancer, autoimmune diseases, and endocrine diseases.
2021: Department for the production of Gam-COVID-Vac (Sputnik Light) vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology.
2021: Plant for hormonal drug production.
2024: Plant for production of heart disease drugs.
2023: Plant for parenteral nutrition production in the Kaluga Special Economic Zone.
2023: Building for general APIs large scale production with an output of 1000 tons per year.
The company employs
highly skilled professionals
There are two innovation drugs:
Pharmasyntez against COVID -19
Production of large-scale batches of the drugs for the treatment of the new coronavirus infection:
A full cycle production including the production of Remdesivir and Favipiravir APIs is carried out at the BratskChemSyntez plant in Bratsk, Irkutsk Region, Russia.
* Included in the treatment regimen for the new coronavirus infection by the Ministry of Healthcare of the Russian Federation